MSCI Inc.
MSCIMSCI Inc.'s balance sheet is under water — net worth is negative, so it owes more than it owns. This is a distressed, high-risk situation — the equity can be wiped by dilution or restructuring before operations recover. Not a value setup.
Biggest watch item: the price is not yet in a confirmed uptrend — timing risk, not thesis risk.
The price is building a base (9 weeks in). But the balance sheet is under water: net worth is negative, so shareholders sit behind everyone the company owes. What settles it: whether the business can earn its way back to positive equity before dilution or restructuring gets there first.
Price story Before the numbers, the tape. A stock price moves through four repeating seasons: a flat base (stage 1), an advance (2), a top (3), a decline (4). Where the price sits in that cycle frames everything below.
MSCI Inc. trades at $541, building a base and 9 weeks into that stage. That is −5.6% against its own 200-day average. It sits at 16% of a 52-week range of $523 to $631. On relative strength it is currently behind the S&P 500 on a trailing-13-week view (9 weeks and counting).
Today the stock is building a base — week 9 of stage 1. At $541 it trades −5.6% versus its 200-day average and sits at 16% of its 52-week range ($523–$631).
Against the market, two honest reads. Cumulative: over the last 10.2 years the stock moved +580% while the S&P 500 moved +255% — ahead of the index over the full window. Recent form: on a trailing-13-week view the stock is currently behind (9 weeks and counting; last ahead the week of 2026-07-17) — the ribbon below is that same metric, week by week.
What would end the trend, mechanically: two Friday closes in a row below the 200-day line. That is the exit rule — no debates.
Valuation For a bank we price the book, not the earnings: P/BV is what the market pays for each $1 of the bank's net worth. A bank below 1× book is priced below the value of what it owns, net of what it owes.
P/BV does not price MSCI Inc. — earnings are negative, so there is no multiple to rank against its own history. The revenue and margin lines below are where a turn, when it comes, would show first. On sales the market values MSCI Inc. at 12.5× its FY25 revenue of $3.1 B.
With earnings negative, P/BV does not price — there is no multiple to rank against its own history. The revenue and margin lines below are where the turn, when it comes, will show first.
Why the multiple sits where it does: over the past year book value grew while the price moved −3.4% — price and book moved together, holding the multiple in its range.
Put together: the multiple is unremarkable against its own past, so the story rests on the book-value line underneath it, not the multiple.
Stage: Mixed Every business sits somewhere on a fundamental arc, and this page names the spot before anything else. The last twelve quarters of revenue, profit and EPS growth — plus the return the business earns on its capital — are read as curves: Deteriorating (the curves are falling), Turning around (a trough has just formed and the last few quarters lift off it), Improving (the climb off the trough is sustained), Consistent (steadily positive with healthy returns), Topping out (still high but decelerating from the peak). When the curves genuinely disagree the read is Mixed; too little history is No read. CAGR (compound annual growth rate) is the smooth yearly pace that turns the starting value into the latest one — the fairest way to compare growth across different time spans. Read the columns together: if the 1-year number towers over the 10-year, recent growth is running hotter than the long-run trend. A dash means that window is not held, or the base year was a loss (where a growth rate is not meaningful).
MSCI Inc. reads as mixed on its fundamental arc. Mixed — the growth curves are steadily positive, but ROE at -45.3% is below the 12% bar this page requires to call it Consistent. The read is built from 12 quarters across 4 curves, on partial evidence.
Why it matters: when the curves disagree, the per-curve reads above matter more than any single verdict.
Return readings here are annual, not quarterly — read as level and direction only; they can confirm the growth curves but never drive the stage on their own.
A partial read: at least one curve is short, or the returns curve is not the computed quarterly series — hold the stage word a little more loosely.
| 1yr | 3yr | 5yr | 10yr | |
|---|---|---|---|---|
| Revenue | +9.4% | +11.6% | — | — |
| Profit | +8.1% | +11.3% | — | — |
| EPS | +11.7% | +13.5% | — | — |
| Stock price | −3.4% | +0.7% | −3.4% | +20.3% |
4-Factor Sector Score
51.1/100 — rank 6 of 14 in Financial Data & Stock Exchanges · 68% evidence confidence
MSCI Inc. scores 51.1 out of 100 against the 14 companies it is compared with in Financial Data & Stock Exchanges, ranking 6. Acceleration candidate, not a confirmed leader: earnings are strong but sector-relative strength is -5.2% and the one-year return is -3.4%. Do not upgrade until sector-relative strength is above zero and another reported period confirms growth.
The four contributions add to the total exactly: 24.8 + 14.4 + 9.8 + 2.1 = 51.1. This is the SAME number shown on the sector comparison — it is computed once, for the whole peer set, and read here.
What would change it: The read weakens if ROA rolls over or gross NPA rises while sector-relative strength deteriorates.
Revenue For a bank, revenue is everything the franchise earns — interest on the loan book plus fees from its businesses.
MSCI Inc. reported $0.9 B of income in the Jun 26 quarter, +13.0% year on year. That is the 12th straight quarter of year-on-year growth. Over 4 years it has compounded at 11.3% a year. The last full year, FY25, came in at $3.1 B. The last four reported quarters add to $3.3 B.
FY25 revenue came in at $3.1 B (+9.4% on the year), capping 4 years at 11.3% compound. The latest quarter (Jun 26) printed $0.9 B, +13.0% year on year — the 12th consecutive quarter of year-over-year growth.
Pace check: the last four quarters averaged +11.7% growth against the decade's 11.3% — the current year is running in line with its own long-run rate.
Acceleration check: trailing-twelve-month revenue grew +11.7% over the last 4 quarters against +10.9%/yr over the last 8 — stabilising; TTM profit +15.3% vs +6.9%/yr — accelerating.
Net margin Net margin — what the bank keeps of every $100 of revenue after every cost, provision and tax. With big fee businesses in the mix, it is the cleanest margin we can read for this bank.
MSCI Inc.'s net margin is 39.1% in the Jun 26 quarter, +0.1 percentage points against the same quarter a year ago. Across 5 fiscal years the net margin has ranged 35.8% to 45.5%. The current quarter sits inside that band.
The latest quarter's net margin is 39.1%, +0.1 pp against the same quarter a year ago. Across 5 fiscal years the net margin has ranged 35.8%–45.5%.
Why: the numbers show the net margin move clearly, but the cost lines behind it sit below what we hold — so we state the move without inventing its driver.
Net profit Net profit is what survives every cost, interest and tax — the number EPS, dividends and book value all grow from.
MSCI Inc. earned $0.3 B of net profit in the Jun 26 quarter, +13.3% year on year. It is the 2nd consecutive quarter of growth. Full-year FY25 profit was $1.2 B. The 4-year compound rate is 13.2%. That is 39.1% of the quarter's revenue. The same quarter a year earlier earned $0.3 B.
Jun 26 profit was $0.3 B, +13.3% year on year — the 2nd consecutive quarter of growth. On the full year, FY25 printed $1.2 B (+8.1%), and the 4-year compound rate is 13.2%.
Why profit moved: revenue contributed +13.0% and the margin +0.1 pp — the quarter was revenue-led, with the margin roughly flat.
Pace comparison, last four quarters: profit +15.7% vs revenue +11.7%. Profit is growing faster than sales — fixed costs are being spread over a bigger base, and each extra dollar of revenue drops more to the bottom line.
Asset quality — the ladder Gross NPA is the slice of the loan book where repayments have stopped. Net NPA is what remains after the money already set aside against those loans. Falling is healing; rising is damage arriving.
Loan-book quality history is not available for MSCI Inc., so this section names the gap rather than estimating a ratio. No gross or net non-performing-asset series is filed in a form this page can read, and none is inferred from the profit line. The income, margin and return sections above carry the evidence this business does report.
We do not hold quarterly loan-book quality numbers for this bank, so this section states that plainly rather than working around it.
Why: loan-book quality is the engine room of a bank, and its drivers — slippages, recoveries, provisioning — sit below what we hold for this name; the sections around it carry the reads we can stand behind.
The loan book We read the loan book through revenue — when the book and the businesses grow, revenue grows with them. It is a rough proxy, and we say so: rate moves and fee swings can shift it a few points in any one year.
MSCI Inc.'s revenue grew +9.4% in FY25 to $3.1 B, so the book is growing. The latest quarter ran +13.0% year on year. The net margin on that income is 39.1%, +0.1 percentage points against a year ago. Interest income is a proxy for the book; rate moves can shift it a few points in any one year.
FY25 revenue was $3.1 B, +9.4% on the year, and the latest quarter ran +13.0% year on year. The net margin on that revenue is 39.1% this quarter (+0.1 pp YoY) — growth with a widening margin on it.
The synthesis: a lender compounds when the book grows while the margin holds and the loan book stays clean — with quarterly loan-quality numbers missing here, revenue growth and margin are the two we watch.
Returns on equity and assets Two numbers rate a bank: ROE — what it earns on shareholder money — and ROA — what it earns on everything it deploys. ROE above ~13–15% earns its keep; below that, growth builds book slowly.
MSCI Inc. earns a return on equity of −45% in FY25. Its trough over the ladder below was −456% in FY21. On the asset side every $100 of the balance sheet earned about $21.13, which is the return before leverage is applied.
FY25 ROE came in at −45%, recovered from a FY21 trough of −456%. On assets, the latest reading is about 21.13% — every $100 the bank deploys earns roughly $21.13 a year. That return is below the bar a bank must clear to compound book value quickly — which is also the honest reason the stock trades where it does.
Why ROE moved: profit compounded 13.2% a year over 4 years while the equity base grew more slowly — earnings recovering faster than book value builds is what lifts ROE off a trough.
Dividend A dividend is cash paid out per share. Dividend per share is the declared amount for the period; the trailing twelve-month total is the four most recent quarters added together.
MSCI Inc. paid $7.70 per share over the last four reported quarters. The most recent declaration was $2.05 for Jun 26. Against the current price of $541 that is a trailing yield of 1.42%, measured on dividends already paid rather than on a forecast.
MSCI Inc. paid $7.70 per share across the last four reported quarters, most recently $2.05 for Jun 26. Against the current price of $541 the trailing twelve months work out to 1.42% — trailing dividends measured against today's price, not a forward estimate.
Debt
For a bank, borrowings are raw material, not a warning sign — solvency is read through the returns and the loan book. A manufacturer’s debt is a claim against its profits, so the debt-to-equity lens that works everywhere else misleads on a lender and is not applied here.
A manufacturer’s debt is a claim against its profits; a bank’s borrowings are its inventory — money taken in to be lent out. The debt lens that works everywhere else misleads here, so this page does not apply it. The solvency questions for a bank — is the loan book sound, is the equity earning — are read through the loan-book and returns sections above.
Ownership There is no quarter-by-quarter holder register to read here, so we read the crowd through short interest — the slice of tradable shares currently sold short, positioned for a fall.
1.7% of MSCI Inc.'s tradable float is currently sold short — the crowd is not positioned against this stock. At typical trading volumes those positions would take about 2.0 days to buy back. There is no quarter-by-quarter holder register to read for this filer, so the crowd is read through short interest instead.
The latest reading: 1.7% of the float is sold short, and at typical trading volumes it would take about 2.0 days to buy those positions back. The crowd is not positioned against this stock. This is a single point-in-time reading — we do not yet hold its history, so we show no trend chart.
Why it sits there: who is doing the shorting, and why, does not travel with the number — the level is shown without inventing its story.
Safety line The Z-score estimates how far a company sits from balance-sheet distress — above roughly 3 is safe, below roughly 1.8 is the danger zone. It was built for manufacturers, so it is not applied to banks and lenders.
MSCI Inc.: the Z-score is omitted — it was built for manufacturers, not banks, and applying it here would be theatre. The Z-score was built for manufacturers and is not applied to banks and lenders, so solvency here is read from the capital and asset-quality lines instead.
The safety line in one sentence: the Z-score is omitted — it was built for manufacturers, not banks, and applying it here would be theatre.
| Company | Score | Price stage | Growth & earnings/35 | Capital efficiency/25 | Valuation/20 | Relative strength/20 |
|---|---|---|---|---|---|---|
| 1Moody's CorporationMCO | 59.0/100Mixed-positive evidence80% evidence | FADING | 28.9/35 Income 11.7% · PAT 31.2% 81% evidence | 20.3/25 ROA 5.2% · ROE 24.2% · GNPA — 68% evidence | 3.5/20 P/BV 25.93× · P/BV÷ROE 1.07 70% evidence | 6.3/20 RS sector -1.8% · RS bench -8.3% · 1Y -3.2%4 of 12 weeks ahead 100% evidence |
| Exact sum: 28.9 + 20.3 + 3.5 + 6.3 = 59 · Decision use: Acceleration candidate, not a confirmed leader: earnings are strong but sector-relative strength is -1.8% and the one-year return is -3.2%. Do not upgrade until sector-relative strength is above zero and another reported period confirms growth. | ||||||
| 2Morningstar, Inc.MORN | 58.3/100Mixed-positive evidence60% evidence | BREAKING OUT | 19.3/35 Income — · PAT — 26% evidence | 15.8/25 ROA 3.1% · ROE 8.2% · GNPA — 68% evidence | 5.8/20 P/BV 6.24× · P/BV÷ROE 0.76 70% evidence | 17.4/20 RS sector 5.3% · RS bench -2.1% · 1Y -13.8%8 of 12 weeks ahead 100% evidence |
| Exact sum: 19.3 + 15.8 + 5.8 + 17.4 = 58.3 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 3Cboe Global Markets, Inc.CBOE | 54.7/100Mixed-positive evidence76% evidence | TURNING | 26.3/35 Income 10.6% · PAT 53.2% 71% evidence | 16.6/25 ROA 3.8% · ROE 7.9% · GNPA — 68% evidence | 7.0/20 P/BV 5.48× · P/BV÷ROE 0.69 70% evidence | 4.8/20 RS sector -3.2% · RS bench -9.2% · 1Y 16%1 of 12 weeks ahead 100% evidence |
| Exact sum: 26.3 + 16.6 + 7 + 4.8 = 54.7 · Decision use: Acceleration candidate, not a confirmed leader: earnings are strong but sector-relative strength is -3.2% and the one-year return is 16%. Do not upgrade until sector-relative strength is above zero and another reported period confirms growth. | ||||||
| 4FactSet Research Systems Inc.FDS | 51.7/100Mixed-positive evidence80% evidence | BREAKING OUT | 10.2/35 Income 6.6% · PAT 6.4% 81% evidence | 16.1/25 ROA 3.2% · ROE 6.1% · GNPA — 68% evidence | 6.7/20 P/BV 4.32× · P/BV÷ROE 0.71 70% evidence | 18.7/20 RS sector 8.5% · RS bench 1.1% · 1Y -4.4%10 of 12 weeks ahead 100% evidence |
| Exact sum: 10.2 + 16.1 + 6.7 + 18.7 = 51.7 · Decision use: Price leads the evidence: RS versus the benchmark is 1.1%, but earnings trajectory is weak. Wait for revenue and profit confirmation. | ||||||
| 5Intercontinental Exchange, Inc.ICE | 51.2/100Mixed-positive evidence80% evidence | BREAKING OUT | 20.9/35 Income 7% · PAT 34.1% 81% evidence | 9.3/25 ROA 0.7% · ROE 3.4% · GNPA — 68% evidence | 8.1/20 P/BV 2.34× · P/BV÷ROE 0.69 70% evidence | 12.9/20 RS sector -0.8% · RS bench -7.5% · 1Y -9.2%4 of 12 weeks ahead 100% evidence |
| Exact sum: 20.9 + 9.3 + 8.1 + 12.9 = 51.2 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 6MSCI Inc.this pageMSCI | 51.1/100Mixed-positive evidence68% evidence | ASLEEP | 24.8/35 Income 11.6% · PAT 15.1% 81% evidence | 14.4/25 ROA 7.3% · ROE -19.1% · GNPA — 68% evidence | 9.8/20 P/BV -15.14× · P/BV÷ROE — 10% evidence | 2.1/20 RS sector -5.2% · RS bench -11.2% · 1Y -3.4%1 of 12 weeks ahead 100% evidence |
| Exact sum: 24.8 + 14.4 + 9.8 + 2.1 = 51.1 · Decision use: Acceleration candidate, not a confirmed leader: earnings are strong but sector-relative strength is -5.2% and the one-year return is -3.4%. Do not upgrade until sector-relative strength is above zero and another reported period confirms growth. | ||||||
| 7Nasdaq, Inc.NDAQ | 50.9/100Mixed-positive evidence80% evidence | TURNING | 22.6/35 Income 7.7% · PAT 30.5% 81% evidence | 14.2/25 ROA 1.9% · ROE 4.3% · GNPA — 68% evidence | 5.4/20 P/BV 3.7× · P/BV÷ROE 0.86 70% evidence | 8.7/20 RS sector -1.3% · RS bench -7.7% · 1Y -0.9%4 of 12 weeks ahead 100% evidence |
| Exact sum: 22.6 + 14.2 + 5.4 + 8.7 = 50.9 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 8TransUnionTRU | 43.6/100Mixed-negative evidence60% evidence | BREAKING OUT | 19.3/35 Income — · PAT — 26% evidence | 11.3/25 ROA 1.6% · ROE 3% · GNPA — 68% evidence | 4.9/20 P/BV 2.85× · P/BV÷ROE 0.95 70% evidence | 8.1/20 RS sector -3.4% · RS bench -9.9% · 1Y -17%8 of 12 weeks ahead 100% evidence |
| Exact sum: 19.3 + 11.3 + 4.9 + 8.1 = 43.6 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 9S&P Global Inc.SPGI | 41.3/100Mixed-negative evidence80% evidence | ASLEEP | 21.2/35 Income 9.7% · PAT 22.4% 81% evidence | 13.9/25 ROA 2.2% · ROE 3.5% · GNPA — 68% evidence | 3.6/20 P/BV 3.81× · P/BV÷ROE 1.09 70% evidence | 2.6/20 RS sector -10.2% · RS bench -16.4% · 1Y -19.8%0 of 12 weeks ahead 100% evidence |
| Exact sum: 21.2 + 13.9 + 3.6 + 2.6 = 41.3 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 10Value Line, Inc.VALU | 41.3/100Mixed-negative evidence70% evidence | BREAKING OUT | 9.1/35 Income -5.6% · PAT 0% 71% evidence | 10.1/25 ROA 0.5% · ROE 5.7% · GNPA — 68% evidence | 8.6/20 P/BV 3.27× · P/BV÷ROE 0.57 70% evidence | 13.5/20 RS sector 4.7% · RS bench -2.2% · 1Y 1.7%8 of 12 weeks ahead 70% evidence |
| Exact sum: 9.1 + 10.1 + 8.6 + 13.5 = 41.3 · Decision use: Price leads the evidence: RS versus the benchmark is -2.2%, but earnings trajectory is weak. Wait for revenue and profit confirmation. | ||||||
| 11MarketWise, Inc.MKTW | 40.3/100Thin evidence · provisional58% evidence | TURNING | 8.6/35 Income -16.2% · PAT -47.1% 71% evidence | 6.0/25 ROA -0.6% · ROE 0.2% · GNPA — 68% evidence | 9.8/20 P/BV -3.87× · P/BV÷ROE — 10% evidence | 15.9/20 RS sector 7.7% · RS bench 1.2% · 1Y 9.6%8 of 12 weeks ahead 70% evidence |
| Exact sum: 8.6 + 6 + 9.8 + 15.9 = 40.3 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 12CME Group Inc.CME | 36.9/100Mixed-negative evidence80% evidence | TURNING | 13.4/35 Income 5.1% · PAT 13.7% 81% evidence | 9.4/25 ROA 0.5% · ROE 3.8% · GNPA — 68% evidence | 5.9/20 P/BV 3.02× · P/BV÷ROE 0.79 70% evidence | 8.2/20 RS sector -1.9% · RS bench -8.4% · 1Y 4.2%1 of 12 weeks ahead 100% evidence |
| Exact sum: 13.4 + 9.4 + 5.9 + 8.2 = 36.9 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 13Coinbase Global, Inc.COIN | 25.0/100Adverse evidence68% evidence | BASING | 4.6/35 Income -10.3% · PAT -134.5% 81% evidence | 5.5/25 ROA -0.4% · ROE -2.9% · GNPA — 68% evidence | 9.8/20 P/BV 2.95× · P/BV÷ROE — 10% evidence | 5.1/20 RS sector -22.3% · RS bench -28.5% · 1Y -52%2 of 12 weeks ahead 100% evidence |
| Exact sum: 4.6 + 5.5 + 9.8 + 5.1 = 25 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 14Securitize Corp.SECZ | 35.9/100Thin evidence · provisional36% evidence | BASING | 18.2/35 Income — · PAT — 15% evidence | 4.9/25 ROA -1.4% · ROE -86.7% · GNPA — 61% evidence | 9.8/20 P/BV -8.19× · P/BV÷ROE — 10% evidence | 3.0/20 RS sector -26.5% · RS bench -31.6% · 1Y -26.2%0 of 12 weeks ahead 70% evidence |
| Exact sum: 18.2 + 4.9 + 9.8 + 3 = 35.9 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
Missing observations are not scored as bad. Their missing weight lowers confidence and pulls the final score toward neutral. Financial companies use P/BV÷ROE and asset quality; PEG, industrial OPM and ROCE are excluded. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led S&P 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step curve the sector itself is placed on — basing, turning, breaking out, leader, fading, asleep — read from how many weeks running it has led S&P 500 and whether that lead is widening or shrinking. It describes where the PRICE stands, not the earnings trajectory and not a recommendation, and it is left blank for a company whose weekly history is too short or too stale to read.
Frequently asked questions
What is MSCI Inc.'s stock price today?
MSCI Inc. trades at $541, −3.4% over the past year. The company is valued at $39.0 B. The stock sits at 16% of its 52-week range of $523–$631, −5.6% versus its 200-day average. On the tape, the price is building a base, 9 weeks in. — as of 17 September 2026.
What were MSCI Inc.'s latest quarterly results?
MSCI Inc. reported total income of $0.9 B and net profit of $0.3 B for the Jun 26 quarter. Income rose 13.0% and profit rose 13.3% year on year. Earnings per share were $4.69. The net margin was 39.1%, 0.1 pp higher than a year earlier. — as of 17 September 2026.
What is MSCI Inc.'s revenue?
MSCI Inc. reported revenue of $0.9 B in the Jun 26 quarter, +13.0% year on year. For the full FY25 fiscal year, revenue was $3.1 B (+9.4%). Over the last 4 years revenue compounded at 11.3% a year. — as of 17 September 2026.
What is MSCI Inc.'s profit?
MSCI Inc. earned $0.3 B of net profit in the Jun 26 quarter, +13.3% year on year — the 2nd straight quarter of growth. Full-year FY25 profit was $1.2 B. The net margin ran 39.1% in the latest quarter. — as of 17 September 2026.
What is MSCI Inc.'s market cap?
MSCI Inc.'s market capitalisation is $39.0 B at a stock price of $541. Market cap is the share price multiplied by shares outstanding, so it is restated whenever the price moves. — as of 17 September 2026.
Does MSCI Inc. pay a dividend?
Yes — MSCI Inc. declared $2.05 per share for Jun 26, and $7.70 per share across the last four reported quarters. — as of 17 September 2026.
What is MSCI Inc.'s dividend per share?
MSCI Inc.'s most recently declared dividend is $2.05 per share for Jun 26, giving $7.70 per share over the trailing twelve months. Each figure is the amount declared for that quarter as reported, added across four quarters for the trailing total. — as of 17 September 2026.
What is MSCI Inc.'s dividend yield?
MSCI Inc.'s trailing dividend yield is 1.42%: $7.70 declared per share across the last four reported quarters, against a share price of $541. Each quarter’s figure is the amount declared for that quarter as reported, added across four quarters and divided by the latest close. — as of 17 September 2026.
Is MSCI Inc. growing?
Yes — MSCI Inc. is growing: latest-quarter revenue +13.0% year on year, profit +13.3%, and the net margin +0.1 pp at 39.1%. The 4-year compound rates are 11.3% (revenue) and 13.2% (profit). The earnings engine currently reads: improving — as of 17 September 2026.
How is MSCI Inc. performing?
MSCI Inc. is building a base, 9 weeks in. Its latest quarter's income rose 13.0% and profit rose 13.3% year on year. Against the S&P 500 it has been behind on a trailing-13-week view for 9 weeks. This describes what the data did, not a rating. — as of 17 September 2026.
What stage is MSCI Inc. in?
Mixed — the growth curves are steadily positive, but ROE at -45.3% is below the 12% bar this page requires to call it Consistent. The read comes from the last 12 quarters of growth (revenue growth +11.7% latest, profit growth +15.3% latest, eps growth +21.1% latest) plus the ROE curve, classified by deterministic rules — a trajectory read, not a buy or sell call — as of 17 September 2026.
Is MSCI Inc. in an uptrend?
No — the price is building a base (week 9 of stage 1), trading −5.6% versus its 200-day average and at 16% of its 52-week range. Price stages cycle base → advance → top → decline, and the stage names where this stock sits in that cycle — as of 17 September 2026.
Is MSCI Inc. beating the market?
Not lately — on a trailing-13-week view MSCI Inc. is currently behind the S&P 500 (9 weeks and counting; last ahead the week of 2026-07-17), the same metric the week-by-week ribbon on this page draws. Separately, on the cumulative view: over the last 10.2 years the stock moved +580% against the S&P 500's +255% — ahead of the index over the full window. — as of 17 September 2026.
Will MSCI Inc.'s stock price go up?
This page publishes no price forecast for MSCI Inc. What it measures instead: the stock price is $541, the price is building a base 9 weeks in. Direction is not something this site claims to know. — as of 17 September 2026.
Is the market betting against MSCI Inc.?
No — short interest is 1.7% of MSCI Inc.'s tradable float, about 2.0 days to cover at typical volumes. That is a low reading: the crowd is not positioned against this stock. With no quarter-by-quarter holder register here, short interest is the cleanest crowd read we hold — as of 17 September 2026.
Where is MSCI Inc. in its business cycle?
MSCI Inc.'s FY25 net margin was 38.3%, against a 5-year band of 35.8%–45.5%: mid-band by its own history — neither the peak that precedes mean-reversion nor the trough that precedes recovery. The latest quarter ran 39.1%. Profitability versus a company's own long band is the cleanest cycle clock this page holds — as of 17 September 2026.
What could break the MSCI Inc. story?
Biggest watch item: the price is not yet in a confirmed uptrend — timing risk, not thesis risk. Mechanically, two Friday closes in a row below the 200-day average would end the price trend — that is the exit rule this page tracks — as of 17 September 2026.
Is MSCI Inc. a stock worth studying right now?
This is not investment advice. The machine read: MSCI Inc.'s balance sheet is under water — net worth is negative, so it owes more than it owns. This is a distressed, high-risk situation — the equity can be wiped by dilution or restructuring before operations recover. Not a value setup. The sharpest open question: whether the business can earn its way back to positive equity before dilution or restructuring gets there first. Every number on this page is drawn deterministically from the raw series, with no forecasts and no price opinions — as of 17 September 2026.
Not SEBI Registered !! Not Investment advice !!